Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Treasury Shares: 2020-2024

Historic Treasury Shares for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $4.0 million.

  • Apellis Pharmaceuticals' Treasury Shares fell 7.91% to $4.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $4.0 million, marking a year-over-year decrease of 7.91%. This contributed to the annual value of $4.0 million for FY2024, which is 7.91% down from last year.
  • Per Apellis Pharmaceuticals' latest filing, its Treasury Shares stood at $4.0 million for FY2024, which was down 7.91% from $4.3 million recorded in FY2023.
  • In the past 5 years, Apellis Pharmaceuticals' Treasury Shares ranged from a high of $4.3 million in FY2023 and a low of $502,000 during FY2020.
  • Its 3-year average for Treasury Shares is $3.9 million, with a median of $4.0 million in 2024.
  • In the last 5 years, Apellis Pharmaceuticals' Treasury Shares surged by 191.59% in 2022 and then declined by 7.91% in 2024.
  • Over the past 5 years, Apellis Pharmaceuticals' Treasury Shares (Yearly) stood at $502,000 in 2020, then surged by 144.02% to $1.2 million in 2021, then soared by 191.59% to $3.6 million in 2022, then increased by 20.41% to $4.3 million in 2023, then declined by 7.91% to $4.0 million in 2024.